Aβ aggregation-IN-7
Aβ aggregation-IN-7 is an orally active, blood-brain barrier-penetrant Aβ1-42 aggregation inhibitor. Aβ aggregation-IN-7 enhances autophagic flux and upregulates the CHIP/STUB1 molecular chaperone, reduces extracellular and intracellular amyloid β oligomer levels, and protects neuronal cells from amyloid β oligomer-induced cytotoxicity and membrane damage. Aβ aggregation-IN-7 rescues spatial learning and memory deficits in vivo, and reduces hippocampal Aβ oligomer burden and brain IFN‑γ inflammatory factor levels. Aβ aggregation-IN-7 can be used for research on Alzheimer's disease.
For research use only. We do not sell to patients.
- Formula: C30H53NO
- Molecular Weight:443.75
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Aβ aggregation-IN-7 (5-20 μM; 24 h) protects SH-SY5Y cells against Aβ1-42 oligomer-induced cytotoxicity and reduces extracellular Aβ oligomer levels in cultures[1].
Aβ aggregation-IN-7 (5-10 μM; 24 h) reduces Aβ oligomer accumulation in SH-SY5Y cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SH-SY5Y cells
-
Concentration:5, 10, 20 μM
15 μM (Aβ1-42 oligomers) -
Incubation Time:24 h
-
Result:Protected SH-SY5Y cells from Aβ1-42 oligomer-induced cytotoxicity, with efficacy plateauing at 10 μM.
-
Cell Line:SH-SY5Y cells
-
Concentration:5, 10 μM
5 μM (Aβ1-42 oligomers) -
Incubation Time:24 h
-
Result:Downregulated intracellular Aβ oligomer accumulation in SH-SY5Y cells at 5 and 10 μM.
-
Cell Line:SH-SY5Y cells
-
Concentration:5, 10, and 20 μM
15 μM (Aβ1-42 oligomers); 20 nM (Bafilomycin A1 (HY-100558)) -
Incubation Time:24 h
-
Result:Bafilomycin A1 partially reversed the cytoprotective effect against Aβ1-42-induced cytotoxicity.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR (healthy, half male and half female, were anesthetized and stereotaxically injected with 10 μg of Aβ1-42 oligomers (5 μL) into the right lateral ventricle)[1]
-
Dosage:50, 100 mg/kg
-
Administration:p.o.; continuous; 21 days
-
Result:Rescued Aβ1-42-induced cognitive impairment and reduces brain Aβ oligomer burden and neuroinflammation in intracerebroventricularly injected ICR mice, with the 100 mg/kg dose producing clear efficacy.
- Protocol for Shuttle Box Test (TDPA)
- Cell Cytotoxicity Assay
- Mammalian live/dead viability and cytotoxicity staining
- Chromatin Immunoprecipitation
- Autophagy
- Protocol for Water Maze
- Macroautophagy Solutions
- Amyloid: Congo Red Amyloid Staining
- Alzheimer’s Disease Modeling
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
Molecular Weight 443.75
-
Formula C30H53NO
-
SMILES
C[C@@H]([C@@]1([H])CC[C@]2(C3=C(CC[C@]12C)[C@@](C)(CC[C@@H]4O)[C@]([H])(C4(C)C)CC3)C)CCCNC(C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Aβ aggregation-IN-7 Related Classifications
HY-190913 Related Classifications
Powered by Bioz
Keywords
- Aβ aggregation-IN-7
- Amyloid-β
- IFNAR
- Autophagy
- β-amyloid peptide
- Aβ
- Abeta
- Interferon-α/β receptor
- Interferon-alpha/beta receptor
- Alzheimer's disease
- Aβ aggregation
- CHIP/STUB1
- amyloid-beta oligomer
- autophagic flux
- blood-brain barrier
- memory deficits
- neuroprotection
- oligomer formation
- spatial learning
- Inhibitor
- inhibitor
- inhibit